View this email in your browser

BIA’s Exosome Pack is available now!

CORNERSTONE Exosome Process Development Pack  
designed to accomodate the special challenges of exosome purification 
BIA Separations is proud to announce a release of a new product for very effective exosome enrichment and reduction of host cell contaminants. It is a unique approach to exosome purification intended to enable the preparation of high quality research-grade exosomes. The process can be easily scaled up or down to meet development, validation, and manufacturing demand.
For more information please download the presentation.

Order now and receive 30% off your first purchase.
Let us do the hard work for you.
Beside column production, BIA offers process development service. For more information please contact us at and ask for CORNERSTONE Exosome DSP Development Service.
Platform Purification of Clinical-Quality Bacteriophages
Antibiotics are unable to keep pace with infectious diseases, and the use of phages is a timely solution to that problem. But their implementation involves overcoming some challenges.
Here you can find more information on BIA Separations' solution for purification of phages.
Product discontinuance notification
BIA Separations has taken the decision to discontinue some of our older products to make room in our line for new technology.  Products of the CIM® disk line will be discontiued as of January 1, 2020. For more information click here.
Application note
The CIMmic™ α-HSA column can be prepared to quantitatively remove HSA and obtain albumin-free samples which can be further processed. The process is described in our new application note "Depletion of human serum albumin from plasma samples by immunoextraction on immobilised immuno-affinity CIMmic™".
We invite you to meet us at
BIA donates for treatment of boy with spinal muscular atrophy
Kris, a 19-month-old boy from Slovenia, was born with spinal muscular atrophy—a rare and devastating genetic disorder that had been incurable until this year's revolutionary launch of gene therapy treatment called Zolgensma. The drug now successfully saves lives of children who would otherwise die before reaching the age of two. BIA's team is proud to announce that treatment with Zolgensma drug was developed with the help of our unique technology, which is used for the purpose of drug purification.

It is a true honor to support the treatment that will save a child's life not only in terms of our scientific contribution but also by a generous financial donation. Sufficient funds, raised in a national-level charity, will help Kris obtain the required treatment.
Confirmed Speakers Include:
  • Venkata Indurthi, Aldevron, USA
  • Andrew Knudten, Gene Therapy Consulting LLC, USA
  • Franz Gerner, RegenxBio, USA
  • Pete Gagnon, BIA Separations, Slovenia
...and many more. Download 2nd Announcement and discover what we have prepared!

Grab your chance! Early bird discount (30% off) prolonged till November 15, 2019.
Copyright © 2019 BIA Separations, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.